Contrast media developer Epix Medical has completed enrollment in the second of two phase III trials designed to detect peripheral vascular disease in the aortoiliac arteries using the company¹s new blood pool MR agent, MS-325. The company expects to
Contrast media developer Epix Medical has completed enrollment in the second of two phase III trials designed to detect peripheral vascular disease in the aortoiliac arteries using the company¹s new blood pool MR agent, MS-325. The company expects to complete a review of the data and release results in spring 2003. Positive study results from the first trial were reported last March at the annual American College of Cardiology meeting. Epix continues to enroll patients in the remaining two phase III clinical trials aimed at detecting peripheral vascular disease in the renal and pedal arteries. Enrollment in these trials should be completed in the first quarter of 2003. Epix plans to file a new drug application with the FDA for MS-325 approximately six months after enrollment is completed.
New Study Finds Racial Disparities with Pre-Op Breast MRI and Positive Surgical Margin Rates
November 8th 2024In addition to a lower rate of preoperative breast MRI use, emerging research found that Black women with breast cancer who didn’t have a preoperative MRI had a higher positive surgical margin rate than White women with no preoperative MRI.
Improving Adherence to Best Practices for Incidental Abdominal Aortic Aneurysms on CT and MRI
November 5th 2024In recent interviews, Eric Rohren, M.D., and Krishna Nallamshetty, M.D., discuss the potential of abdominal aortic aneurysms (AAAs) to progress into life-threatening consequences and an emerging AI-powered tool that may bolster adherence to best practice recommendations in radiology reporting of incidental AAA findings on CT and MRI.